Inventiva/$IVA

1D1W1MYTD1Y5YMAX

About Inventiva

Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
Ticker
$IVA
Sector
Health
Primary listing
NASDAQ
Employees
73
Headquarters
Daix, France
Website
inventivapharma.com

Inventiva Metrics

BasicAdvanced
$793M
-
-$1.05
-
-

Bulls say / Bears say

NATiV3 has reached its last-patient-last-visit milestone after 72 weeks of treatment in 1,009 main-cohort patients, plus 410 in an exploratory cohort. The Q4 2026 topline readout is now the key near-term catalyst; positive data could support regulatory filings in the first half of 2027. (GlobeNewswire)
Lanifibranor has a differentiated pan-PPAR mechanism intended to address metabolic, inflammatory and fibrotic drivers of MASH. Recent company-reported Phase 1 and Phase 2 findings showed target engagement and improvements in several metabolic measures, while the FDA has granted Breakthrough Therapy and Fast Track designations. (GlobeNewswire)
Recent financing gives Inventiva a clearer path to the Phase 3 readout: management says completed equity and debt transactions should fund planned operations through the end of the second quarter of 2027. That reduces the immediate risk of having to pause NATiV3 before its results are available. (GlobeNewswire)
Inventiva remains a clinical-stage company with no approved products or product-sales history, and lanifibranor is its sole major value driver. The investment is therefore highly dependent on one programme producing successful Phase 3, regulatory and commercial outcomes. (GlobeNewswire, StockAnalysis.com)
Funding is not fully secure beyond the near term. Inventiva says current cash alone is insufficient for the next 12 months, while the longer runway depends on additional debt proceeds and the full exercise of warrants, creating refinancing and potential dilution risk. (GlobeNewswire)
Safety and regulatory uncertainty has not been eliminated: Inventiva says a suspected unexpected serious adverse reaction could still affect NATiV3’s final results, timing or related regulatory matters. The company also stresses that a positive Data Monitoring Committee recommendation would not itself predict marketing authorisation. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 24 Sept 2026.

Inventiva News

AllArticlesVideos

Inventiva Q2 Earnings Call Highlights

MarketBeat17 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.